Hydroxyurea (Droxia)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Sickle Cell Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Sickle Cell Disease

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Sickle Cell Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Hydroxyurea (Droxia): this drugApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Crizanlizumab-Tmca (Adakveo)ApprovedMonoclonal antibodyP-selectinPartial signalFeatured results are non-efficacy only in this race
Exagamglogene Autotemcel (Casgevy)ApprovedGene therapy / editingBCL11A erythroid enhancer (gene editing)Weak signalNo reviewed efficacy summary in this indication
Hydroxyurea (Siklos)ApprovedSmall moleculeRibonucleotide reductasenot yet gradedNo reviewed efficacy summary in this indication
Hydroxyurea (Xromi)ApprovedSmall moleculeRibonucleotide reductaseWeak signalNo reviewed efficacy summary in this indication
L-Glutamine (Endari)ApprovedSmall moleculeAmino AcidReliable signal
NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15)
Lovotibeglogene Autotemcel (Lyfgenia)ApprovedGene therapy / editingBeta-globin gene addition (betaA-T87Q)not yet gradedNo reviewed efficacy summary in this indication
EtavopivatPhase 3—Pyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Mitapivat (Pyrukynd)Phase 3Small moleculePyruvate kinasenot yet gradedNo reviewed efficacy summary in this indication
Decitabine / Tetrahydrouridine (NDec)Phase 2Small moleculeDNMT1 (DNA methyltransferase 1)not yet gradedNo reviewed efficacy summary in this indication
HBI-002Phase 2Small moleculeCarbon monoxide (CO)-based gas therapeutic; oral liquid CO formulationnot yet gradedNo reviewed efficacy summary in this indication
ITU512Phase 1/2Small moleculeWIZ transcription factornot yet gradedNo reviewed efficacy summary in this indication
Nula-CelPhase 1/2Gene or cell therapy (subtype unspecified)HBB gene (sickle mutation correction)not yet gradedNo reviewed efficacy summary in this indication
Ristoglogene AutogetemcelPhase 1/2Gene therapy / editingHBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
DISC-3405Phase 1Monoclonal antibodyTMPRSS6 (matriptase-2)not yet gradedNo reviewed efficacy summary in this indication
SCD-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
VAS-101Phase 1——not yet gradedNo reviewed efficacy summary in this indication
Iloprost (Ventavis)DiscontinuedSmall moleculeIP receptor (prostacyclin pathway)not yet gradedNo reviewed efficacy summary in this indication
Renizgamglogene AutogedtemcelDiscontinuedGene or cell therapy (subtype unspecified)HBG1/HBG2 promotersnot yet gradedNo reviewed efficacy summary in this indication
Voxelotor (Oxbryta)DiscontinuedSmall moleculeHemoglobin S (HbS)Reliable signal
NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92

Upcoming events

No upcoming readouts on record for this asset.